GlassScriptPhysician profile
Teodor Duro
NPI 1780180315
$6,402.19
in general payments reported to CMS, 2019-2025
16 companies · $4,893 in 2025
The $4,893 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $257 · 2023: $680 · 2024: $451 · 2025: $4,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,492 · Food and Beverage: $2,231 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,492.00 |
| Food and Beverage | $2,231.43 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $3,713.40 | 2025 | |
| Medtronic, INC. | $434.43 | 2024-2025 | Minimed 780g |
| Amgen INC. | $428.72 | 2022-2025 | Evenity |
| Chiesi USA, INC. | $300.00 | 2025 | Myalept |
| Xeris Pharmaceuticals, INC. | $244.18 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Novo Nordisk INC | $228.05 | 2023-2025 | Ozempic, Levemir, Victoza |
| Insulet Corporation | $180.32 | 2023-2025 | Omnipod |
| Radius Health, INC. | $135.00 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.40 | 2021 | |
| Averitas Pharma INC. | $121.36 | 2023 | Qutenza |
| Lilly USA, LLC | $112.64 | 2023 | Mounjaro |
| Corcept Therapeutics | $111.14 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $81.36 | 2022 | |
| Horizon Therapeutics Plc | $80.85 | 2023 | Tepezza |
| Ultragenyx Pharmaceutical INC. | $80.19 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $29.15 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teodor Duro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.